A multicenter, randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability, and amyloid-imaging positron emission tomography (PET) trial of AAB 001 (ELN115727) [bapineuzumab] in patients with mild to moderate Alzheimer's disease (AD).

Trial Profile

A multicenter, randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability, and amyloid-imaging positron emission tomography (PET) trial of AAB 001 (ELN115727) [bapineuzumab] in patients with mild to moderate Alzheimer's disease (AD).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2012

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2010 Results from a substudy measuring cerebrospinal fluid tau proteins presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010 (Abstract O3-05-01), according to a Intellect Neurosciences media release.
    • 10 Jul 2010 Substudy results and pooled analysis of substudies presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
    • 01 Apr 2010 Results published in Lancet Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top